ストックスクリーナーアプリを入手
1.1002
8.33%
-0.0998
Enlivex Ltd (ENLV) 最新ニュース
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt - The Manila Times
Enlivex (NASDAQ: ENLV) highlights Rain AI launch, $5M grants and RAIN token burn - Stock Titan
One prompt can now create a live prediction market as Rain adds $5M - Stock Titan
Enlivex Obtains $21 Million Loan to Purchase RAIN Tokens and Initiate $20 Million Buyback - Bitget
Enlivex shares jump after earnings as treasury gains boost results - MSN
Envilex Therapeutics (ENLV) Reports Strong FY GAAP EPS - GuruFocus
Enlivex Soars After FDA Approval for Allocetra Trial - StocksToTrade
Enlivex Stock Boosted by FDA Approval for Allocetra in Osteoarthritis Trials - timothysykes.com
Enlivex Allocetra Takes A Leap as FDA Clears Phase 2b Trial for Osteoarthritis - timothysykes.com
Enlivex Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Enlivex Q4 2025 sees stock surge on treasury gains - Investing.com
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48 - Bitget
Enlivex Posts $1.23B Profit (Net Income) For Fiscal 2025 - Benzinga
Enlivex Posts $1.23 Billion Profit for 2025 on Treasury Asset Gains - TipRanks
Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS - MarketBeat
Enlivex Ltd. Reports $1.23 Billion Net Income for 2025 Driven by Treasury Asset Appreciation - Quiver Quantitative
Biotech–crypto hybrid Enlivex (NASDAQ: ENLV) outlines RAIN treasury risks and funding needs - Stock Titan
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted ... - Bluefield Daily Telegraph
Enlivex (NASDAQ: ENLV) nets $1.23B in 2025 on digital treasury gains - Stock Titan
Treasury gains push Enlivex to $1.23B profit, $2.31B in assets - Stock Titan
Strategic Move: Enlivex Allocates $21 Million for RAIN Token Acquisition Amid Share Buyback - MEXC
Enlivex Raises $21 Million to Expand RAIN Token Treasury Holdings - Blockonomi
Enlivex Raises $21M to Expand RAIN Token Treasury and Biotechnology Pipeline - MoneyCheck
Enlivex Secures $21M Funding to Boost RAIN Treasury Strategy - CoinCentral
Off The Hook Yachts and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Enlivex stock rating held at Hold by D. Boral Capital after debt deal - Investing.com Australia
Enlivex Funding Rounds, Token Sale Review & Tokenomics Analysis - CryptoRank
Enlivex secures $21M debt financing, buys more RAIN tokens - Investing.com
Enlivex Secures $21 Million Convertible Debt, Expands RAIN Token Holdings and Launches $20 Million Buyback - TipRanks
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program - The Manila Times
Enlivex (Nasdaq: ENLV) adds $21M financing and $20M share repurchase plan - Stock Titan
Backed by $21M debt, Enlivex buys 3B more RAIN tokens at discount - Stock Titan
Enlivex secures $21M debt financing, buys more RAIN tokens By Investing.com - Investing.com India
FDA clears Enlivex knee osteoarthritis therapy for phase 2b trial By Investing.com - Investing.com Australia
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis - Stocktwits
Enlivex (ENLV) Gains FDA Approval for Osteoarthritis Drug Trial - GuruFocus
Enlivex Therapeutics announces FDA clearance of Allocetra new drug application - TipRanks
Enlivex Gets Investigational New Drug Clearance in US for Phase 2b Trial of Knee Osteoarthritis Treatment - marketscreener.com
Enlivex Wins FDA IND Clearance for Global Phase 2b Trial of Allocetra in Knee Osteoarthritis - TipRanks
FDA clears Enlivex (Nasdaq: ENLV) Phase 2b Allocetra trial in knee osteoarthritis - Stock Titan
FDA clears Enlivex study for knee arthritis drug in older adults - Stock Titan
Enlivex Therapeutics Tokenized Stock (Ondo) price today, ENLVon to USD live price, marketcap and chart - CoinMarketCap
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Monday - Defense World
CEO Change: How does Enlivex Therapeutics Ltd score in quality rankings2026 Volume Leaders & AI Optimized Trade Strategies - baoquankhu1.vn
Aug Rallies: Can Enlivex Therapeutics Ltd sustain earnings growthPrice Action & Community Verified Watchlist Alerts - baoquankhu1.vn
AI Stocks: Is Enlivex Therapeutics Ltd in a long term uptrend2026 Bull vs Bear & Real-Time Price Movement Reports - baoquankhu1.vn
Enlivex Ltd.: Fundamental Analysis and Financial Ratings | 1BT | IL0011319527 - marketscreener.com
ENLV (NASDAQ: ENLV) trims ATM program to $250M, prior sales noted - Stock Titan
Enlivex Ltd.: Fundamental Analysis and Financial Ratings | ENLV | IL0011319527 - marketscreener.com
EBIT per share of Enlivex Ltd. – LS:A119KH - TradingView
Nasdaq Moves: Can Enlivex Therapeutics Ltd reach all time highs this year - baoquankhu1.vn
Sentiment Recap: How does Enlivex Therapeutics Ltd score in quality rankings2026 Spike Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Enlivex (ENLV) CEO details direct holdings of shares and stock options - Stock Titan
Enlivex (ENLV) CFO discloses initial share and option holdings - Stock Titan
Enlivex (ENLV) director Hart Gili reports option and share holdings - Stock Titan
Enlivex (ENLV) director discloses major share and option stake - Stock Titan
Enlivex (NASDAQ: ENLV) director reports options on 150,000 shares in Form 3 - Stock Titan
Enlivex (NASDAQ: ENLV) director discloses share and option stake - Stock Titan
Enlivex (ENLV) CMO discloses initial share and stock option holdings - Stock Titan
Published on: 2026-03-17 18:55:28 - baoquankhu1.vn
Operating cash flow per share of Enlivex Ltd. – SWB:1BT - TradingView
0.99%
3.03%
大文字化:
|
ボリューム (24 時間):